Top Biogen Scientist Departs, Strikes Out with “Stealth Mode” Startup

John Beaver, PhD spent 7.5 years at central nervous system-focused biotech firm Biogen. In fact, in his last position, he was Vice President, Head of Biomarkers, Imaging, Bioanalytical Services &amp; Pathology according to his LinkedIn profile.&nbsp; TrialSite questioned the decision making of the Food and Drug Administration (FDA) when the agency approved the Alzheimer&rsquo;s drug Aduhelm during summer of 2021.&nbsp; By December 2022 Arnie Mazer confirmed TrialSite&rsquo;s concerns of pharma and FDA &ldquo;coziness&rdquo; over that and other approvals. &nbsp;Dr. Beaver departed from the prominent Cambridge, MA-based biotech in October 2023, and according to his LinkedIn, is launching a startup.
Referred to just as &ldquo;Stealth Mode Biotech&rdquo; the loss of Dr. Beaver was significant. He has led teams of over 100 scientists delivering innovative biomarker and pharmacology data as part of initiatives to accelerate 48 programs including that industry first FDA accelerated approval of biomarkers in Alzheimer&rsquo;s and ALS.